Full-Time

Associate Medical Science Liaison

Updated on 9/3/2026

Sirtex

Sirtex

201-500 employees

Targets liver tumors with radioembolization beads

Compensation Overview

$138k - $173k/yr

+ 15% target bonus

Phoenix, AZ, USA

Remote

Must live in Arizona, California, New Mexico, or Nevada. Travel up to 50% with periodic weekend work.

PharmD, PhD, MD

Category
Biology & Biotech

Get referred to Sirtex

See people who can refer or advise you

Requirements
  • An advanced life sciences or healthcare degree is required, such as a Doctor of Philosophy, Doctor of Pharmacy, or Doctor of Medicine.
  • At least one year of experience in the pharmaceutical or medical device industries, including in-house cross-functional experience in medical science liaison or a comparable industry role.
  • Strong leadership qualities and the ability to influence and motivate team members.
  • Ability to align with multiple internal and external stakeholders and work cross-functionally in a matrix structure.
  • Ability to work in a dynamic, fast-paced team environment with strong attention to detail, organization, operational effectiveness, project strategy development, reliable project implementation, and a flexible, solution-driven approach.
  • Ability to travel up to 50% of the time with periodic weekend work for conferences or other meetings.
Responsibilities
  • Support the clinical and commercial development of SIR-Spheres and other products marketed in the United States through outreach to and collaboration with key opinion leaders, healthcare professionals, and external stakeholders.
  • Establish new relationships with key experts and healthcare professionals while cultivating existing relationships in collaboration with commercial and cross-functional partners.
  • Conduct outreach to investigators, key opinion leaders, and community physicians.
  • Identify key speakers and support speaker training.
  • Identify participants for the Sirtex fellowship program and develop and execute the program.
  • Provide fair and balanced medical information to physicians in accordance with the United States label for Sirtex products.
  • Serve as a company spokesperson on clinical programs, clinical trials, and marketing functions requiring clinical or medical translation.
  • Identify and develop relationships with key opinion leaders and accomplished physicians who influence liver cancer management.
  • Develop key opinion leader engagement plans and support relationship management and healthcare professional education.
  • Share feedback and issues from external experts with internal commercial leaders.
  • Represent Sirtex at medical meetings, conferences, advisory boards, outreach meetings, and interactions with thought leaders and strategic corporate partners.
  • Identify potential proctors and new users requiring proctoring and support their introduction to the TEC program.
  • Collaborate with regional commercial counterparts and the Medical Affairs Manager to identify healthcare professionals for engagement.
  • Identify fellowship participants and new speakers and support speaker development.
  • Use the Evidence Generation Plan to identify potential drivers of investigator-sponsored research and engage with them as they develop study proposals.
  • Update Sirtex leadership on study progress and identify and mitigate delays or barriers with investigators in the region.
  • Deliver medical education presentations in varied settings and collect feedback for dissemination throughout the organization.
  • Coordinate with Medical Information to address healthcare professional inquiries promptly and follow up as needed.
  • Work with medical science liaisons to generate insight questions, identify broader implications, and present healthcare professional insights and corresponding actions to the Medical team and leadership.
  • Translate healthcare professional insights into scientific communications and publication deliverables.
  • Support internal training efforts, including Journal Club, commercial training, and newsletter development.

Sirtex provides liver-directed cancer treatment using SIR-Spheres Y-90 resin microspheres delivered through the hepatic artery to irradiate liver tumors from within. The tiny beads lodge in tumor vessels and emit radiation, killing cancer cells while minimizing exposure to healthy tissue. This catheter-based internal radiation therapy (SIRT) is distinct from external beam radiation or systemic drugs, with a history of regulatory approvals in the US and Europe and a shift from public to private ownership. The goal is to offer effective, targeted radiotherapy for inoperable liver tumors and expand access to SIRT globally, maintaining leadership in this specialized field.

Company Size

201-500

Company Stage

Acquired

Total Funding

$30K

Headquarters

Sydney, Australia

Founded

1997

Get referred to Sirtex

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Europe MDR certification on September 16, 2024 opened SIROS rollout across Europe.
  • FLEXdose SELECT launched August 5, 2024, improving scheduling and patient-specific dosing.
  • LAVA expanded Sirtex into embolization after October 27, 2023 commercial availability.

What critics are saying

  • Sirtex depends on one flagship franchise; any SIR-Spheres manufacturing failure cripples revenue.
  • China Grand and CDH control exposes Sirtex to approval delays and geopolitical scrutiny.
  • A quality recall or FDA action on SIR-Spheres ends the company.

What makes Sirtex unique

  • SIR-Spheres became the only U.S.-approved radioembolization for HCC and mCRC on July 7, 2025.
  • DOORwaY90 posted 90% complete responses and 100% local control in April 2026.
  • SIROS and FLEXdose SELECT package personalized Y-90 delivery beyond the base product.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Health Insurance

Paid Sick Leave

Paid Vacation

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
BioPharmaTrend
Sep 16th, 2024
Sirtex's Precision Radiation Spheres Gain EU Certification

Sirtex Medical, a company known for developing treatments for liver cancer, has received EU certification for its SIR-Spheres Y-90 resin microspheres and launched its new SIROS Delivery System in Europe.

PR Newswire
Aug 5th, 2024
Sirtex Medical Launches Sir-Spheres® Flexdose Select Delivery Program To Enable More Selective Y-90 Treatment Plans

Sirtex announces SIR-Spheres® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plansWOBURN, Mass., Aug. 5, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer.SIR-Spheres® FLEXdose SELECT Delivery Program offers unparalleled flexibility by enabling tailored, patient-specific dosing from a single 3mL delivery vial. This program also marks the availability of 3mL SIR-Spheres® vials, which contain a reduced volume of microspheres (approximately 27 million compared to 44 million in the current 5mL vials). With up to five days pre-calibration available every day of the week, the novel Y-90 delivery program offers a vial of SIR-Spheres® designed for more selective treatment targeting."We're pleased to introduce this latest innovation in Y-90 radioembolization therapy to treat a broader spectrum of tumor burden," said Matt Schmidt, CEO of Sirtex Medical Limited. "The SIR-Spheres® FLEXdose SELECT Delivery Program reflects our continued focus on listening to the needs of patients and physicians by enabling access to personalized Y-90 resin doses and expedited patient treatments.""I have found the SIR-Spheres® FLEXdose Program to be extremely helpful in treating my patients on a timely basis," explained Ripal Ghandi, M.D., a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute and the course director for the Symposium on Clinical Interventional Oncology. "With this program, I can personalize the Y-90 treatment for each of my patients using a product that is available every day of the week

Yahoo Finance
Mar 25th, 2024
Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member

Sirtex Medical appoints Matt Schmidt as new chief executive officer and board of directors member.

Manchester Times
Nov 13th, 2023
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO

Mr. Smith joins Inogen from Sirtex Medical Limited, a previously ASX-listed leading manufacturer of interventional treatment solutions, where he most recently served as Chief Executive Officer since 2019.

PR Newswire
Oct 27th, 2023
Sirtex Medical Announces Commercial Availability Of New Lava® Liquid Embolic System

Sirtex unveils first-of-its-kind product to treat peripheral vascular hemorrhageWOBURN, Mass., Oct. 27, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.LAVA® provides volume and viscosity options that optimize the flexibility needed to treat patients with controlled target vessel occlusion. The product's 2mL and 6mL options are optimized for the peripheral vasculature, and its viscosity options allow for the distal embolization of small vessels that may be inaccessible via other embolics."This product's ability to maximize the packing density within the target vessel is incredibly important, as it allows us to minimize the likelihood of a future recurrence or restoration of vessel patency," said Dr. Gary Siskin, Professor and Chairman of the Department of Radiology at Albany Medical Center.In a study of the LAVA® Liquid Embolic System for the embolic treatment of arterial hemorrhage in peripheral vasculature, the product met both the primary safety and effectiveness endpoints, with 100% of patients experiencing no major adverse events in 30 days and 94% of lesions meeting clinical success in 30 days."The trial was an incredible success. Our goal was to achieve 70% efficacy for the existing data and outcomes, but we were able to achieve 94% efficacy," said Dr. Bulent Arslan, Professor of the Division of Interventional Radiology and Director of Vascular and Interventional Radiology at RUSH Medical College